Although hyperhomocysteinemia has been recognized recently as a prevalent risk factor for myocardial infarction and stroke, the mechanisms by which it accelerates arteriosclerosis have not been elucidated, mostly because the biological effects of homocysteine can only be demonstrated at very high concentrations and can be mimicked by cysteine, which indicates a lack of specificity. We found that 10 -50 M of homocysteine (a range that overlaps levels observed clinically) but not cysteine inhibited DNA synthesis in vascular endothelial cells (VEC) and arrested their growth at the G 1 phase of the cell cycle. Homocysteine in this same range had no effect on the growth of vascular smooth muscle cells (VSMC) or fibroblasts. Homocysteine decreased carboxyl methylation of p21 ras (a G 1 regulator whose activity is regulated by prenylation and methylation in addition to GTP-GDP exchange) by 50% in VEC but not VSMC, a difference that may be explained by the ability of homocysteine to dramatically increase levels of S-adenosylhomocysteine, a potent inhibitor of methyltransferase, in VEC but not VSMC. Moreover, homocysteine-induced hypomethylation in VEC was associated with a 66% reduction in membrane-associated p21 ras and a 67% reduction in extracellular signal-regulated kinase 1/2, which is a member of the mitogen-activated protein (MAP) kinase family. Because the MAP kinases have been implicated in cell growth, the p21 ras
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Arteriosclerosis and its complications (such as myocardial infarction, stroke, and peripheral vascular disease) are the leading causes of death in developed countries (1) . Elevated blood levels of homocysteine, an intermediate metabolite of methionine, are an important and independent risk factor for arteriosclerosis (2) (3) (4) (5) (6) (7) . In the Framingham Study, for example, 21% of the population in this large prospective trial had homocysteine levels that would increase the risk of a heart attack by 3.4-fold (4, 5) . Despite the importance of homocysteine as a risk factor, however, the mechanisms by which it induces arteriosclerosis are not understood.
Vascular endothelial cells (VEC) 1 have been implicated in the pathogenesis of arteriosclerosis (1) . VEC normally insulate the vessel wall from circulating phagocytes and platelets. In response to various stimuli and injuries, damaged VEC attract phagocytes and produce cytokines and growth factors that act on neighboring vascular smooth muscle cells (VSMC) to promote their growth. Damaged VEC also allow platelets to adhere to the vessel wall and promote the formation of thrombi. For these reasons previous studies of homocysteine have focused on its effects on VEC (8 -13) . High concentrations of homocysteine (greater than 1 mM) damage VEC, inhibit thrombomodulin secretion and protein C activation, reduce the number of cellular binding sites for tissue plasminogen activator, and impair endothelium-derived vasorelaxation (8 -13) . Unfortunately, it has been difficult to correlate these in vitro observations with clinical observations because the levels of homocysteine studied usually exceed by about 100-fold the levels found in the population at risk. In addition, most (if not all) of the biological effects of homocysteine can be mimicked by cysteine or other sulfhydryl-containing agents (9, 14) . Therefore a mechanism unique to homocysteine has yet to be identified. Cellular methylation, which regulates gene expression (15, 16) and modifies protein function (17) (18) (19) (20) , cannot occur without the action of methyltransferase (21) . Homocysteine (but not cysteine) is efficiently converted to a potent inhibitor of methyltransferase, S-adenosylhomocysteine (SAH), in the presence of adenosine (22) (23) (24) . To elucidate the role of homocysteine in the development of arteriosclerosis, we studied its effect at low doses on VEC proliferation and p21 ras methylation. We found that clinically relevant concentrations of homocysteine but not cysteine inhibited proliferation of VEC in a cell type-specific manner. This inhibition of VEC growth was associated with an increase in the level of SAH, a reduction in p21 ras methylation and membrane association, and a reduction in mitogen-activated protein (MAP) kinase activity.
MATERIALS AND METHODS
Cell Culture-Human umbilical vein endothelial cells (HUVEC) and human aortic endothelial cells (HAEC) (Clonetics Corp, San Diego, CA) were grown in M199 medium (JRH Biosciences, Lenexa, KS) containing 20% fetal calf serum (Hyclone Laboratories), 50 g/ml endothelial cell * This work was supported in part by a grant from Bristol-Myers Squibb. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. (25, 26) .
Cell Proliferation Analysis-HAEC (2-5 ϫ 10 5 cells/cm 2 ) were plated onto six-well plates and cultured to 25-30% confluence. The cells were then cultured with fresh medium containing 50 M adenosine and 10 M EHNA and exposed to L-cysteine, L-cystine, DL-homocysteine, Lhomocystine, or L-homocysteine thiolactone. Medium and chemicals were changed every other day. Cells were harvested by trypsinization, and cell number was determined in triplicate in a hemocytometer (Coulter Electronics, Hialeah, FL) at 2-day intervals.
Fluorescence-activated Cell Sorting Analysis-HAEC (2-5 ϫ 10 5 cells/cm 2 ) were plated onto 100-mm dishes and cultured to 70 -80% confluence. Thereafter the cells were cultured in fresh medium containing 50 M adenosine and 10 M EHNA plus 50 M DL-homocysteine or L-cysteine. After 24 h the cells were harvested, washed twice with phosphate-buffered saline/0.1% dextrose, and fixed in 70% ethanol at 4°C. The fixed cells were stained with propidium iodine (50 g/ml)/ DNase-free RNase (2 units/ml) at room temperature for 1 h and subjected to fluorescence-activated cell sorting analysis of DNA content as described (27) .
Two-dimensional Thin Layer Chromatography Analysis-HAEC and HASMC were plated onto six-well plates and grown to 70 -80% confluence. The cells were then cultured with fresh medium containing 50 M adenosine and 10 M EHNA plus L-cysteine or DL-homocysteine and labeled metabolically with [8- 14 C]adenosine (1 Ci/ml, NEN Life Science Products, 50 mCi/mmol) for 5 h. Thereafter cells were extracted twice with 0.125 ml of 1 M formic acid. The levels of SAH and Sadenosylmethionine (SAM) were determined by two-dimensional thin layer chromatography as described by Jakubowski and Goldman (28, 29) . In brief, after the extract had been centrifuged the supernatant was lyophilized and dissolved in 20 l of water. Each sample (10 l) was then applied to polyethyleneimine-cellulose plates (10 ϫ 10 cm, J. T. Baker). Butanol/acetic acid/water (4:1:1 by vol) and 3 M (NH 4 ) 2 SO 4 /2% disodium EDTA were used as the first-and second-dimension solvents, respectively. Standard compounds were also applied to the plate as a reference, and their location was determined by exposure to UV light. The radioactivity of 14 C-labeled SAH and SAM was measured on a PhosphorImager running the ImageQuant software (Molecular Dynamics, Sunnyvale, CA). 35 S]methionine (1170 Ci/mmol, NEN Life Science Products) for the last 12 h. Cells were extracted with 1 ml of lysis buffer (10 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 M pepstatin, 100 units aprotinin/ml, and 1 M phenylmethanesulfonyl fluoride, pH 7.2). Protein (100 g) was immunoprecipitated with 5 g of agarose-linked rat antibody against v-H-ras (Y13-259, Oncogene) and resolved by 12% SDS-PAGE for 3 h. We excised the L-[methyl-
3 H]methionine-labeled p21 ras protein from the gel by using L-[ 35 
S]methionine-labeled p21
ras protein as a size marker. Carboxyl methylation of p21 ras was measured by alkaline hydrolysis of protein methyl esters in a vapor phase assay as described (30) with slight modification. Dried gel slices were mixed with 100 l of 1 M sodium hydroxide in a 1.5-ml microcentrifuge tube. This tube was placed carefully into a 22-mm polyethylene scintillation vial containing 5 ml of the aqueous scintillation mixture Econo-safe (Research Products International Corp) for 24 h at 37°C. L-methyl-3 H-Labeled methanol transferred from base-hydrolyzed protein esters was measured in a liquid scintillation counter. The vapor phase transfer efficiency of volatile methanol was determined in a control experiment in which 10 l of [ 14 C]methanol was added to 100 l of 1 M sodium hydroxide as described above. About 65-70% of the radioactivity present in the original sample was transferred to the scintillation mixture under these conditions.
Membrane Purification and Immunoprecipitation-HAEC at 70 -80% confluence were cultured in fresh medium containing 50 M adenosine and 10 M EHNA plus 50 M DL-homocysteine or L-cysteine for 24 h. The cells were labeled metabolically with 200 -300 Ci/ml L-[ 35 S]methionine (1170 Ci/mmol, NEN Life Science Products) for the last 12 h. Whole cell extracts were harvested with 0.5 ml of standard RIPA buffer. Membrane fractions were harvested with 0.5 ml of ice-cold homogenizing buffer (10 mM Tris-HCl, 1 mM EDTA, 5 mM dithiothreitol, 1% Triton X114, 10 M phenylmethanesulfonyl fluoride, and 1 ϫ protease inhibitor mixture) and purified as described (18) with slight modification. After a 10-min incubation on ice, nuclei were pelletized and removed by centrifugation. The supernatant was then warmed to 37°C for 2 min. The aqueous and detergent phases were separated by spinning for 2 min in a microfuge. Membrane fractions in the detergent phase were then diluted nine times with homogenizing buffer to which no Triton X114 had been added. Protein (100 g) was immunoprecipitated with 5 g of agarose-linked rat antibody against v-H-ras and then resolved by 12% SDS-PAGE. Immunoprecipitated p21 ras was measured on a PhosphorImager running the ImageQuant software.
In-gel MAP Kinase Assay-HAEC and HASMC at 70 -80% confluence were cultured in fresh medium containing 50 M adenosine and 10 M EHNA plus 50 M DL-homocysteine or L-cysteine for 24 h. Cells were extracted with 1 ml of isolation buffer (20 mM HEPES, pH 7.2, 25 mM KCl, 5 mM MgCl 2 , 5 mM NaF, 1 mM ATP, 2 mM phenylmethanesulfonyl fluoride, 1 mM Na 4 VO 3 , 0.1 mg/ml aprotinin, and 250 mM sucrose). In-gel MAP kinase activity was measured by a myelin basic kinase assay (31) . Protein samples (20 g) were separated by 12% SDS-PAGE with 0.5 mg/ml myelin basic protein (Sigma). After electrophoresis, the gel was washed twice with 50 mM Tris-HCl pH 8/20% isopropanol for 1 h, washed once with 50 mM Tris-HCl pH 8/5 mM ␤-mercaptoethanol for 1 h, denatured by two washes with 6 M guanidine HCl for 1 h, renatured overnight in 50 mM Tris-HCl pH 8/0.04% Tween 40/5 mM ␤-mercaptoethanol, and then incubated for 1 h in kinase reaction solution (40 mM HEPES, pH 8, 0.5 mM EGTA, 10 mM MgCl 2 , 2 mM A kinase inhibitory peptide, 40 mM ATP, and 25 Ci of [␥-32 P]ATP). The gel was washed extensively with 5% trichloroacetic acid/1% tetrasodium pyrophosphate before drying and autoradiography. MAP kinase activity was determined in a PhosphorImager running the ImageQuant software.
RESULTS

Homocysteine but Not Cysteine Inhibits Proliferation in Vascular Endothelial Cells-Incubation of HUVEC for 24 h with 50
M adenosine and 10 M EHNA, an adenosine deaminase inhibitor (added to prolong the extremely short half-life of adenosine in culture), had little effect on [
3 H]thymidine incorporation and cell growth (data not shown). However, in the presence of adenosine and EHNA, homocysteine and homocystine (the oxidized form) decreased [
3 H]thymidine incorporation in a dosedependent manner (Fig. 1) . As little as 20 M homocysteine decreased DNA synthesis by more than 50% in HUVEC. In marked contrast, neither cysteine nor cystine (the oxidized form) had any effect on DNA synthesis in HUVEC. This inhibitory effect was not species-specific, because homocysteine also inhibited [
3 H]thymidine uptake in both HAEC and porcine aortic endothelial cells (Fig. 1) . Homocysteine had no inhibitory effect on [ 3 H]thymidine incorporation in HASMC (Fig. 1) or in human or mouse fibroblasts (data not shown), suggesting that this inhibitory effect is cell type-specific.
To determine whether decreases in cell number followed homocysteine-induced decreases in DNA synthesis, we counted the number of HAEC in the presence of adenosine and EHNA 2, 4, and 6 days after addition of homocysteine or cysteine. Consistent with their inhibitory effect on [ 3 H]thymidine incorporation, homocysteine, homocystine, and homocysteine thiolactone but not cysteine or cystine markedly decreased cell number in a time-and dose-dependent manner (Fig. 2) . Although the inhibitory effect of 25 M homocysteine was not evident until day 4, a decrease in cell number in the presence of 50 M homocysteine was detectable as early as day 2 (Fig. 2) .
We then subjected HAEC to flow cytometric analysis 24 h after addition of homocysteine to define its effect on the cell cycle. A representative experiment is shown in Fig. 3A , and the percentage of cells in each phase of the cell cycle (from three independent experiments) is shown in Fig. 3B . Homocysteine but not cysteine increased the number of cells in the G 1 phase from 65 to 85% and decreased the number in the S phase from 20 to 6% (Fig. 3, A and B) . In contrast, homocysteine had no effect on the number of cells in the G 2 /M phase. Thus, homocysteine appears to block the cell cycle in G 1 or at the G 1 /S junction.
Homocysteine Increases S-Adenosylhomocysteine in Vascular Endothelial but Not Smooth Muscle Cells-
In the presence of adenosine and SAH synthetase, homocysteine should increase the level of SAH, a potent inhibitor of methyl transfer reactions involving SAM (22, 23, 32, 33) . The ratio of SAH to SAM represents a measure of cellular methylation status (34 -36) . To determine the effect of homocysteine on the SAH/SAM ratio in vascular cells, we metabolically labeled homocysteine-or cysteine-treated HAEC and HASMC with [ 14 C]adenosine and analyzed extracts prepared from the two cell types by twodimensional thin layer chromatography. A representative gel is shown in Fig. 4 . (The graph shows the average SAH/SAM ratio from three independent experiments.) Homocysteine (but not cysteine) markedly increased the level of SAH in HAEC (Fig. 4) and increased the SAH/SAM ratio by 6 -8-fold. It had little effect on the ratio in HASMC. These results suggest that homocysteine-induced increases in the SAH/SAM ratio (and subsequent cellular hypomethylation) may mediate inhibition of VEC growth by homocysteine. Also, the differential effect of homocysteine on VEC and VSMC growth may be explained by its ability to dramatically increase the SAH/SAM ratio in HAEC but not HASMC.
Homocysteine Decreases p21 ras Methylation and Membrane Association and MAP Kinase Activity in HAEC-The G 1 regulator p21
ras is essential for cell growth. p21 ras activity depends on its ability to associate with the cell membrane, which is mediated by a series of post-translational modifications that include prenylation and carboxyl methylation of the p21 ras C terminus (17, 18, 20, 37 (30) . p21 ras carboxyl methylation was inhibited by 50% in HAEC treated for 24 h with homocysteine but not in HAEC treated with cysteine (Fig. 5 ). In contrast, homocysteine did not decrease p21 ras carboxyl methylation in HASMC (Fig. 5) , an observation consistent with our finding that homocysteine had no effect on DNA synthesis (Fig.  1 ) and the SAH/SAM ratio (Fig. 4) in HASMC.
We then determined whether hypomethylation of p21 ras reduced its ability to associate with the cell membrane. Equal amounts of [ 35 S]methionine-labeled HAEC (treated for 24 with homocysteine or cysteine) whole cell extract or membrane fraction were immunoprecipitated with the anti-v-H-ras antibody and then analyzed by 12% SDS-PAGE. In HAEC whole cell extract, homocysteine did not affect the abundance of p21 ras protein (Fig. 6A) . In HAEC membrane fraction, however, homocysteine decreased membrane-associated Ras by 66%. Because membrane association of Ras and subsequent activation leads to the sequential activation of Raf and MAP kinases, homocysteine-induced decreases in the membrane association of Ras could lead to reductions in MAP kinase activity. Therefore we studied the effect of homocysteine on MAP kinase activity by an in-gel assay. Homocysteine but not cysteine decreased the activity of extracellular signal-regulated kinase (ERK) 1/2 (the major MAP kinase isoforms in VEC) by 66% in HAEC (Fig. 6B) . In contrast, homocysteine failed to decrease ERK1/2 activity in HASMC. Because ERK activation is important for cellular proliferation (38, 39) , these data are consistent with our observation that homocysteine decreased DNA synthesis in HAEC but not HASMC (Fig. 1) . In the quiescent state, control HUVEC had more ERK1/2 activity than homocysteinetreated HUVEC. Serum induced less ERK1/2 activity in homocysteine-treated HUVEC than in controls (Fig. 7) . In contrast, 3 H]Thymidine incorporation was measured in a liquid scintillation counter (25, 26) . The values represent the means Ϯ S.D. from three independent experiments from three wells (n ϭ 9).
homocysteine had no effect on induction of ERK1/2 in HASMC. These data suggest that the reduction in Ras membrane localization in HUVEC and the subsequent decreases in ERK1/2 activity in HUVEC are biologically significant.
DISCUSSION
To our knowledge this is the first demonstration that a biological response can be induced by clinically relevant levels of homocysteine but not cysteine. The growth inhibitory effect of homocysteine on VEC occurred at concentrations that overlap the elevated blood homocysteine levels (15-20 M) observed in 21% of the patients in the Framingham Study (4, 5) . Furthermore, the effect of homocysteine was cell type-specific, because homocysteine inhibited growth in VEC but not in VSMC or fibroblasts. It is also important to point out that the oxidized form of homocysteine, homocystine, also inhibited VEC proliferation (Figs. 1 and 2) . Most of the homocysteine in blood is in the oxidized form (40 -42) .
Although 10 -50 M of homocysteine markedly inhibited VEC growth in the presence of adenosine (Figs. 1 and 2 ), these same levels of homocysteine had no effect in the absence of adenosine (data not shown). Because adenosine by itself has little effect on VEC growth, these data suggest that the inhibitory effect of homocysteine is mediated, at least in part, by its ability to reduce cellular methylation. This possibility is supported by our observation that homocysteine markedly increased the levels of SAH (and the SAH/SAM ratio) in HAEC but not HASMC (Fig. 4) . Although we do not know why the 
FIG. 5. Decrease in p21
ras carboxyl methylation in HAEC treated with homocysteine. HAEC and HASMC were incubated on 100-mm 2 dishes for 24 h in medium containing 50 M adenosine and 10 M EHNA (control) plus 50 M DL-homocysteine or L-cysteine. After the protein had been immunoprecipitated and resolved, carboxyl methylation was measured (with L-[
35 S]methionine-labeled p21 ras protein used as size marker) by alkaline hydrolysis of protein methyl esters in a vapor phase assay as described (30) . The values represent the means Ϯ S.D. from three independent experiments (n ϭ 3). *, p Յ 0.005. effect of homocysteine is selective for VEC, it is possible that homocysteine is transported across the cell membrane faster in VEC than in other cell types such as HASMC and fibroblasts. This selective sensitivity could also be the result of an increase in the activity of SAH synthetase in VEC, which would lead to increased SAH levels in the presence of equivalent concentrations of adenosine and homocysteine.
Methylation of a protein's C terminus is a reversible and common post-translational modification (17, 21) . Methylation affects the function of a protein by increasing its hydrophobicity or its ability to associate with the cell membrane. For example, carboxyl methylation is essential for the efficient binding of prenylated p21
k-ras to the membrane (18) and for the recruitment to the membrane (in chemoattractant-stimulated neutrophils) of the Ras-related protein p22 rac2 and the G protein ␥ subunit (20, 37) . Inhibitors of prenylcysteine carboxyl methylation block the response of neutrophils to chemoattractants (20, 37) , and carboxyl methylation increases the activity of the retinal transducin T␤␥ (19, 43) . These observations are consistent with our finding that homocysteine-induced decreases in p21 ras methylation are associated with a decrease in membrane association in HAEC and a decrease in the activity of the MAP kinase ERK1/2. Because the MAP kinases have been implicated in cell growth (38, 39) , the p21 ras -MAP kinase pathway may represent one of the mechanisms that mediates the inhibitory effect of homocysteine on VEC growth. However, we cannot be certain that homocysteine's growth inhibitory effect is mediated solely by the p21 ras -MAP kinase pathway. Studies are underway to determine whether hypomethylation of other cellular macromolecules, such as lamin B or protein phosphatase 2A (44, 45) , also contributes to the growth inhibitory effect of homocysteine.
Because endothelial cell injury is thought to play a key role in the development of arteriosclerosis, homocysteine-induced inhibition of proliferation and p21
ras methylation in these cells may have an important effect on arteriosclerotic lesion formation. The inhibitory effect of homocysteine on VEC methylation and growth in conjunction with our previous finding that 100 M homocysteine (a level observed in patients with homocystinuria) stimulates proliferation of VSMC (25, 26) may represent an important link between homocysteine and arteriosclerosis. FIG. 7 . Decrease in ERK1/2 activity stimulated by serum in homocysteine-treated HUVEC but not HASMC. HUVEC and HASMC were incubated on 100-mm 2 dishes for 24 h with 50 M adenosine and 10 M EHNA (control) plus 50 M DL-homocysteine (as in Fig.  1 ). To make the cells quiescent, we reduced the serum concentration to 5% for HUVEC (for 24 h; further reduction of the concentration would have led to VEC death) and to 0.4% for HASMC (for 72 h). Cells were stimulated with or without serum for 30 min. Protein was extracted, and the in-gel MAP kinase assay was performed as described for Fig. 6.   FIG. 6 . A, decrease in membrane-associated but not total p21 ras in HAEC treated with homocysteine. HAEC were incubated on 100-mm 2 dishes for 24 h with 50 M adenosine and 10 M EHNA (control) plus 50 M DL-homocysteine or L-cysteine (as in Fig. 1 ). The membrane fraction was purified with Triton X114 as described under "Materials and Methods." B, decrease in activity of the MAP kinase ERK1/2 in HAEC treated with homocysteine. HAEC and HASMC were incubated on 100-mm 2 dishes for 24 h with 50 M adenosine and 10 M EHNA (control) plus 50 M DL-homocysteine or L-cysteine. ERK1/2 was localized according to prestained protein standards in the same gel. A and B, p21 ras (Ras) was immunoprecipitated as described under "Materials and Methods." MAP kinase activity (measured by the density of the bands) was determined in a PhosphorImager running the ImageQuant software. The control value was set at 100%. The values represent the means Ϯ S.D. from three independent experiments (n ϭ 3). *, p Յ 0.005.
